Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;100(1):23-32.
doi: 10.1002/ajh.27510. Epub 2024 Nov 18.

Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries

Christian Récher  1 , Pierre-Yves Dumas  2 , Emilie Bérard  3 , Suzanne Tavitian  1 , Thibaut Leguay  2 , Jean Galtier  2 , Camille Alric  1 , Audrey Bidet  4 , Eric Delabesse  5 , Jean Baptiste Rieu  5 , Jean-Philippe Vial  4 , François Vergez  5 , Isabelle Luquet  5 , Emilie Klein  4 , Anne-Charlotte de Grande  2 , Audrey Sarry  1 , Sven Zukunft  6 , Uwe Platzbecker  7 , Carsten Müller-Tidow  8 , Claudia D Baldus  9 , Martin Bornhäuser  6 , Hubert Serve  10 , Sarah Bertoli  1 , Arnaud Pigneux  2 , Christoph Röllig  6
Affiliations

Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries

Christian Récher et al. Am J Hematol. 2025 Jan.

Abstract

According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini-consolidations (idarubicin 8 mg/m2 day 1, cytarabine 50 mg/m2/12 h, day 1-5) and IDAC. Inclusion criteria were newly diagnosed AML, age > 60 years, first CR after induction and at least 1 cycle of consolidation. Of the 796 included patients, 322 patients received mini-consolidations and 474 patients received IDAC. Mini-consolidation patients were older, and more often, they had de novo AML and unfavorable risk. The rate of allogeneic transplantation was higher in the IDAC group. The median number of cycles was higher in the mini-consolidation group (4 vs. 2; p < .0001). Median relapse-free survival was 18 months with mini-consolidations and 12 months with IDAC (p = .0064). In multivariate analysis, the risk of relapse or death was significantly higher in the IDAC group (p = .004). Median OS was 36 versus 31 months with mini-consolidations or IDAC, respectively (p = .46). In multivariate analysis, the consolidation regimen had no significant influence on OS (p = .43). In older AML patients, post-remission therapy with mini-consolidations represents an alternative to IDAC.

PubMed Disclaimer

Conflict of interest statement

Christian Récher declares a consulting or advisory role with AbbVie, Amgen, Astellas, BMS, Boehringer, Jazz Pharmaceuticals, J&J, and Servier, research funding from AbbVie, Amgen, Astellas, BMS, Iqvia, and Jazz Pharmaceuticals, and support for attending meetings and/or travel from AbbVie, Novartis, and Servier. Pierre‐Yves Dumas declares a consulting or advisory role for Daiichi‐Sankyo, Astellas, Novartis, AbbVie, Servier, BMS, Jazz Pharmaceutical, and Janssen, research funding (to institution) from Daiichi‐Sankyo, Astellas, Novartis, Servier, BMS, Roche, and Iqvia, and support for attending meetings and/or travel from AbbVie, Gilead, and Lilly.François Vergez declares research grants from Pierre Fabre and Roche, advisor for Astellas and Amgen. Uwe Platzbecker declares Honoraria and Research support from BMS, AbbVie, Curis, Jazz, and Ryvu. Isabelle Luquet declares an advisory role for Jazz Pharmaceuticals. Carsten Müller‐Tidow declares institutional research funding from Pfizer and BiolineRx. LR declares institutional research funding from AbbVie and honoraria from BeiGene, Jazz, and Neovii. Claudia Baldus declares advisory honoraria from Astellas, Bristol‐Meyer‐Squibb, Jazz, Janssen, Pfizer, Servier, Amgen, and Astra Zeneca. Martin Bornhäuser declares honoraria from Jazz Pharmaceuticals Advisory Board: ActiTrexx; employment by University Hospital TU Dresden, King's College London. Sarah Bertoli declares a consulting or advisory role with AbbVie, Astellas, BMS‐Celgene, Jazz Pharmaceuticals, and Servier and travel grants from AbbVie and Pfizer. Arnaud Pigneux declares a consulting or advisory role with Astellas, BMS, Servier, AbbVie, Gilead, Jazz Pharmaceuticals, Novartis, and Pfizer, research funding from Astellas, BMS, Roche, and Servier, and support for attending meetings and/or travel from Servier and AbbVie. Christoph Röllig declares institutional research funding by AbbVie, Novartis, and Pfizer and advisory honoraria from AbbVie, Astellas, Bristol‐Meyer‐Squibb, Jazz, Janssen, Novartis, Otsuka, Pfizer, and Servier. All other authors declare no competing interests.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curves for overall survival (A), cumulative incidence of relapse (B), and relapse‐free survival (C). [Color figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. - PubMed
    1. Récher C, Röllig C, Bérard E, et al. Long‐term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2022;36(4):913‐922. - PMC - PubMed
    1. Jimenez‐Chillon C, Dillon R, Russell N. Optimal post‐remission consolidation therapy in patients with AML. Acta Haematol. 2024;147(2):147‐158. - PMC - PubMed
    1. Luger SM. Is the current consolidation regimen for AML evidence‐based? Best Pract Res Clin Haematol. 2021;34(4):101334. - PubMed
    1. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N Engl J Med. 1994;331(14):896‐903. - PubMed

MeSH terms

LinkOut - more resources